... 边缘带淋巴瘤 marginal zone lymphoma 骨髓原始细胞 marrow blast 最大耐受剂量 maximum tolerated dose ...
基于10个网页-相关网页
...Kirstetter 研究小组通过RT-PCR,发现与HSC扩增有关的基因(Cdkn1a,Hoxb4,Bmi1)和与骨髓原始细胞(Myeloid progenitor cell)形成有关的基因(Sfp1)表达显著下降,而PU.1异位表达引发的erythroid分化能力丧失导致GATA-1表达量下降。
基于8个网页-相关网页
骨髓原始细胞(bone marrow blast cell,BMblast)比率≤50%者中位生存期(98天)显著长于>50%者(55天)(P=0.006);预后良好核型者中位...
基于4个网页-相关网页
骨髓原始细胞(bone marrow blast cell,BMblast)比率≤50%者中位生存期(98天)显著长于>50%者(55天)(P=0.006);预后良好核型者中位...
基于2个网页-相关网页
骨髓原始细胞减少指数(MBDI)作为临床疗效判定指标之一。
Marrow blast decrease index (MBDI) was valued as an index of clinical chemotherapeutic effects.
在任何一个亚型中,治疗均与急性髓系白血病转化率无关,包括骨髓原始细胞增多或有异常核型出现的患者。
Treatment was not linked to the rate of acute myeloid leukemia in any defined subgroup, including patients with an increase of marrow blasts or an unfavorable karyotype.
另有12名患者为骨髓缓解,即骨髓原始细胞低于5%,还有8名患者治疗后骨髓原始细胞下降了50%以上。
An additional 12 patients experienced a bone marrow response resulting in less than 5% bone marrow blasts, and another 8 patients had bone marrow blast reductions of more than 50% with treatment.
应用推荐